John Chiplin
Executive Director
Biopharma
Benitec Biopharma
Australia
Biography
John Chiplin, PhD, has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions that Dr. Chiplin has been instrumental in include Benitec BioPharma (US IPO), Medistem (acquired by Intrexon), Arana Therapeutics (acquired by Cephalon), and Domantis (acquired by GSK). Immediately prior to running Arana, Dr. Chiplin was head of the ITI Life Sciences investment fund in the UK, negotiating significant funding with Government Ministers. Dr. Chiplin’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on the boards of Adalta, Batu Biologics, Benitec BioPharma (NASDAQ: BNTC), The Coma Research Institute, Cynata Therapeutics (ASX:CYP.AX), Prophecy (Chairman), Scancell Holdings plc (LSE: SCLP.L, Chairman), ScienceMedia, and Sienna Cancer Diagnostics.
Research Interest
Life Sciences
